Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob et al. · The Lancet Oncology · 2015
Cited by 1,261 works. doi:10.1016/s1470-2045(15)70122-1
Authors
- Alexander M.M. Eggermont
- Vanna Chiarion‐Sileni
- Jean‐Jacques Grob
- Reinhard Dummer
- Jedd D. Wolchok
- Henrik Schmidt
- Omid Hamid
- Caroline Robert
- Paolo A. Ascierto
- Jon M. Richards
- Célèste Lebbé
- Virginia Ferraresi
- Michael Smylie
- Jeffrey S. Weber
- Michele Maio
- Cyril Konto
- Axel Hoos
- Veerle de Pril
- Ravichandra Karra Gurunath
- Gaetan de Schaetzen
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Final Version of 2009 AJCC Melanoma Staging and Classification
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases
- Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
- Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
- Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials